Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service dialysis access cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (245 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 184 | 26,428 | 46% |
| 2020 | 166 | 24,877 | 48% |
| 2021 | 161 | 21,766 | 51% |
| 2022 | 136 | 17,456 | 53% |
| 2023 | 122 | 15,286 | 55% |
| 2024 | 109 | 13,452 | 57% |
| 2025 from claims | – | 12,174 11,173–12,880 | 58% |
| 2026 forecast | – | 12,281 10,806–14,172 | 58% |
| 2027 forecast | – | 12,335 10,545–14,699 | 59% |
| 2028 forecast | – | 12,386 10,335–15,167 | 59% |
| 2029 forecast | – | 12,436 10,157–15,596 | 60% |
| 2030 forecast | – | 12,484 10,001–15,998 | 60% |
AV fistula and graft creation, access circuit angioplasty and stenting. Professional codes (what the surgeon bills): CPT 36821, 36830, 36902, 36903, 36905, 36906, 36818, 36819.
Since 2021 dialysis (ESRD) patients may join Medicare Advantage, and they have moved to it far faster than the county average, so fee-for-service decline here overstates the real one even after adjustment.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 43% of the cases CMS names in New York; 36 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 17% hospital outpatient, 11% surgery center, 69% office. The share outside the hospital has moved +4 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~12,300 | ~360 | ~2,100 | ~1,600 | ~8,200 |
| 2027 · ~12,300 | ~360 | ~2,100 | ~1,700 | ~8,200 |
| 2028 · ~12,400 | ~360 | ~2,100 | ~1,800 | ~8,200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 14% (11% in 2025), office about 66% (69% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New Jersey | 58 | 7,071−13%/yr | −13%/yr | 7.0 | 70% | 7,590 in 2030+1.2%/yr |
| Pennsylvania | 59 | 4,916−14%/yr | −14%/yr | 3.8 | 50% | 4,300 in 2030−2.2%/yr |
| Massachusetts | 31 | 2,905−7.2%/yr | −7.2%/yr | 3.2 | 22% | 3,070 in 2030+0.9%/yr |
| Connecticut | 14 | 1,941−9.9%/yr | −9.9%/yr | 6.1 | 87% | 1,830 in 2030−1%/yr |
| Rhode Island | 3 | 655−9.9%/yr | −9.9%/yr | 7.5 | 100% | 610 in 2030−1.3%/yr |
| New Hampshire | 6 | 354−13%/yr | −13%/yr | 1.6 | 0% | 380 in 2030+1.2%/yr |
| Maine | 4 | 340−15%/yr | −15%/yr | 2.2 | 5% | 390 in 2030+2.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 97 | 12,468−0.1%/yr | −0.1%/yr | 6.51.5× | 60% | 16,300 in 2030+4.6%/yr |
| Superficial venous ablation | 132 | 8,630−5.2%/yr | −5.2%/yr | 4.51.6× | 97% | 9,880 in 2030+2.3%/yr |
| Thrombectomy, IVC filters & venous stents | 24 | 2,696−2.3%/yr | −2.3%/yr | 1.51.2× | 17% | 3,720 in 2030+5.5%/yr |
| Carotid revascularization | 32 | 1,508−6.4%/yr | −6.4%/yr | 0.80.7× | 0% | 1,510 in 20300%/yr |
| Aortic endografts (EVAR/TEVAR) | 7 | 818−5.7%/yr | −5.7%/yr | 0.51.1× | 0% | 860 in 2030+0.8%/yr |
Dialysis access in every state, and its device makers · Every procedure market in New York · Every state · Compare with New Jersey
BD leads with 45% of company spending on these surgeons in 2025, +43 pts on 2024.
In 2025, 9 companies reported engagement with New York’s surgeons worth $11K in consulting, speaking, meals and travel tied to these products, about $100 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 948 dialysis fistulas and shunts stays at 36 hospitals in 2024, against the Medicare-only figures above.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| NYU LANGONE HOSPITALS NEW YORK | 73 | 56% | — |
| MOUNT SINAI HOSPITAL NEW YORK | 69 | 67% | — |
| LONG ISLAND JEWISH MEDICAL CENTER NEW HYDE PARK | 69 | 68% | — |
| MONTEFIORE MEDICAL CENTER BRONX | 69 | 64% | — |
| NORTH SHORE UNIVERSITY HOSPITAL MANHASSET | 56 | 61% | — |
| MOUNT SINAI WEST NEW YORK | 52 | 85% | — |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 46 | 61% | — |
| NEW YORK-PRESBYTERIAN/BROOKLYN METHO BROOKLYN | 37 | 62% | — |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (Dialysis fistulas and shunts). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.